LFCR
Lifecore Biomedical, Inc. (LFCR) Porter's 5 Forces Analysis (2026)
No material changes this month.
Overall Score
Threat Of New Entrants
Moderate barriers to entry due to the need for clinical expertise, regulatory compliance, and payer relationships.
Scale and established distribution still matter, but the business is not protected by a strong moat.
Bargaining Power Of Suppliers
Supplier power appears manageable given the company’s current liquidity and working capital position.
No fresh evidence of a major supply-chain disruption or concentration risk this month.
Bargaining Power Of Buyers
Buyer power remains meaningful because customers and payers can pressure pricing in a competitive healthcare services market.
Weak profitability and negative margins limit pricing leverage, but a 3.87 current ratio suggests near-term operating flexibility.
Threat Of Substitutes
Substitution risk remains moderate as alternative care pathways and competing service models can divert demand.
No new product or reimbursement news materially changed the substitution outlook this month.
Industry Rivalry
Rivalry is elevated because the company is operating with negative EBIT and net margins, which typically intensifies competition for volume and pricing.
High leverage and weak cash generation increase the pressure to defend share in a crowded market.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lifecore Biomedical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.